A common gut bacterium is quietly tied to stomach cancer decades later

One of the most common chronic infections on Earth lives silently in the human stomach, often taking hold in childhood and staying for life without producing a single symptom. That bacterium, Helicobacter pylori, colonizes the stomach lining of roughly half the world’s population, and in most people it never causes obvious trouble. Yet decades of epidemiology have established it as the single largest infectious cause of stomach cancer, a disease that frequently goes undetected until it is advanced.

The connection is not a fringe hypothesis. Health agencies classify the bacterium as a definite human carcinogen, and researchers estimate that the majority of stomach cancers worldwide trace back to it. Understanding how a common stomach bug becomes a long-term cancer risk helps explain why physicians increasingly test for and treat the infection even in people who feel perfectly well.

How Helicobacter pylori survives in stomach acid

Helicobacter pylori is a spiral-shaped bacterium uniquely adapted to one of the harshest environments in the body. As documented in its microbiology, it produces large amounts of the enzyme urease, which converts urea into ammonia and neutralizes acid in the immediate area around the microbe. Its corkscrew shape and whip-like flagella let it burrow through the protective mucus layer and settle against the stomach wall, where the pH is closer to neutral.

Transmission usually happens person to person, often within families and typically in early childhood, through saliva, vomit, or fecal contamination of food and water. Once established, the infection tends to persist for the host’s lifetime unless it is deliberately treated with antibiotics. Because it rarely announces itself, most carriers have no idea they harbor it.

The slow path from inflammation to cancer

The bacterium’s danger lies in the chronic inflammation it provokes. Persistent infection irritates the stomach lining, producing gastritis that can, over many years, progress through a recognized sequence: atrophy of the stomach glands, a change in the lining called intestinal metaplasia, then dysplasia, and finally cancer. This cascade typically unfolds over decades, which is why a childhood infection can surface as disease in later life.

Only a minority of infected people ever reach the end of that path. Roughly 1 to 3 percent of carriers develop gastric adenocarcinoma, and about 0.1 percent develop a rarer stomach lymphoma known as MALT lymphoma. But because so many people carry the bacterium, even small percentages translate into an enormous global toll.

Not every strain carries the same danger. Certain variants of the bacterium produce a protein called CagA that is injected directly into stomach-lining cells and interferes with their normal signaling, and infections with these strains are associated with a substantially higher risk of severe disease. Host genetics, diet, salt intake, and smoking further modify who progresses, which helps explain why most carriers stay healthy while a subset develop cancer decades on.

Why agencies call it a group 1 carcinogen

The International Agency for Research on Cancer classified H. pylori as a group 1 carcinogen in 1994, the highest category reserved for agents with sufficient evidence of causing cancer in humans. The U.S. National Toxicology Program similarly lists chronic infection with the bacterium as a known human carcinogen in its Report on Carcinogens. Pooled analyses of prospective studies have found that infected people carry several times the risk of non-cardia gastric cancer compared with uninfected people.

The scale of the burden is striking. An IARC analysis attributed roughly 660,000 cancer cases in a single year to the bacterium, a figure amounting to about 5 percent of all cancers globally at the time. Stomach cancer remains one of the leading causes of cancer death worldwide, and the infection sits behind the large majority of cases.

What treatment and eradication can do

Because the link is causal rather than coincidental, clearing the infection can lower risk. Standard therapy combines two or more antibiotics with an acid-suppressing drug, usually taken for one to two weeks. Diagnosis does not require an invasive procedure in most cases; a breath test, stool antigen test, or blood antibody test can detect it, though testing after treatment is important to confirm the microbe is gone.

Evidence that eradication reduces cancer risk has grown stronger over time. An updated meta-analysis of eradication trials and cohort studies found that successfully treating the infection was associated with a lower subsequent incidence of gastric cancer, with the benefit most pronounced in regions where the disease is common. That has prompted some countries with high stomach cancer rates to consider population-wide screen-and-treat programs.

Why the risk stays hidden for so long

The long silence between infection and disease is what makes the bacterium so consequential. A microbe acquired before adolescence may quietly drive inflammation for forty or fifty years before any tumor appears, and early stomach cancer often produces vague symptoms such as indigestion or mild discomfort that are easy to dismiss. By the time alarming signs emerge, the disease is frequently advanced.

That delayed timeline is also why the infection is often described as a preventable cause of cancer rather than an inevitable one. Detecting and eliminating the bacterium interrupts the inflammatory process before it can complete its decades-long march, turning a lifelong stowaway into a manageable, treatable condition rather than a hidden threat. For a bacterium that most of its carriers will never notice, that quiet, decades-deep link to one of the world’s deadliest cancers is a reminder that some of the most consequential health risks are the ones that produce no symptoms at all until it is late.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview